Bimekizumab
Indication
Active psoriatic arthritis (NICE TA916)
NICE TA916 - Bimekizumab for treating active psoriatic arthritis
Brand:
Nice TA:
916
Commissioning responsibility:
CCG
PbR excluded:
Yes
Background
1.1 Bimekizumab alone or with methotrexate, is recommended as an option for treating active psoriatic arthritis (defined as peripheral arthritis with 3 or more tender joints and 3 or more swollen joints) in adults whose condition has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them. It is recommended only if they have had 2 conventional DMARDs and:
-
at least 1 biological DMARD or
-
tumour necrosis factor (TNF)-alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis).
Bimekizumab is recommended only if the company provides it according to the commercial arrangement.